S&P 500   4,247.89 (-0.60%)
DOW   33,370.72 (-0.74%)
QQQ   353.59 (-0.18%)
AAPL   170.10 (-1.08%)
MSFT   311.81 (-0.11%)
META   299.41 (+0.15%)
GOOGL   129.77 (+0.93%)
AMZN   125.16 (-0.65%)
TSLA   237.60 (-2.67%)
NVDA   419.22 (+0.03%)
NIO   8.35 (-0.71%)
BABA   85.75 (-0.19%)
AMD   97.53 (+1.64%)
T   14.81 (-1.40%)
F   12.34 (-0.72%)
MU   67.23 (-1.05%)
CGC   0.87 (-6.20%)
GE   111.15 (+1.11%)
DIS   79.38 (-0.84%)
AMC   7.79 (-1.52%)
PFE   32.00 (-1.23%)
PYPL   57.09 (-3.12%)
NFLX   378.79 (-0.12%)
S&P 500   4,247.89 (-0.60%)
DOW   33,370.72 (-0.74%)
QQQ   353.59 (-0.18%)
AAPL   170.10 (-1.08%)
MSFT   311.81 (-0.11%)
META   299.41 (+0.15%)
GOOGL   129.77 (+0.93%)
AMZN   125.16 (-0.65%)
TSLA   237.60 (-2.67%)
NVDA   419.22 (+0.03%)
NIO   8.35 (-0.71%)
BABA   85.75 (-0.19%)
AMD   97.53 (+1.64%)
T   14.81 (-1.40%)
F   12.34 (-0.72%)
MU   67.23 (-1.05%)
CGC   0.87 (-6.20%)
GE   111.15 (+1.11%)
DIS   79.38 (-0.84%)
AMC   7.79 (-1.52%)
PFE   32.00 (-1.23%)
PYPL   57.09 (-3.12%)
NFLX   378.79 (-0.12%)
S&P 500   4,247.89 (-0.60%)
DOW   33,370.72 (-0.74%)
QQQ   353.59 (-0.18%)
AAPL   170.10 (-1.08%)
MSFT   311.81 (-0.11%)
META   299.41 (+0.15%)
GOOGL   129.77 (+0.93%)
AMZN   125.16 (-0.65%)
TSLA   237.60 (-2.67%)
NVDA   419.22 (+0.03%)
NIO   8.35 (-0.71%)
BABA   85.75 (-0.19%)
AMD   97.53 (+1.64%)
T   14.81 (-1.40%)
F   12.34 (-0.72%)
MU   67.23 (-1.05%)
CGC   0.87 (-6.20%)
GE   111.15 (+1.11%)
DIS   79.38 (-0.84%)
AMC   7.79 (-1.52%)
PFE   32.00 (-1.23%)
PYPL   57.09 (-3.12%)
NFLX   378.79 (-0.12%)
S&P 500   4,247.89 (-0.60%)
DOW   33,370.72 (-0.74%)
QQQ   353.59 (-0.18%)
AAPL   170.10 (-1.08%)
MSFT   311.81 (-0.11%)
META   299.41 (+0.15%)
GOOGL   129.77 (+0.93%)
AMZN   125.16 (-0.65%)
TSLA   237.60 (-2.67%)
NVDA   419.22 (+0.03%)
NIO   8.35 (-0.71%)
BABA   85.75 (-0.19%)
AMD   97.53 (+1.64%)
T   14.81 (-1.40%)
F   12.34 (-0.72%)
MU   67.23 (-1.05%)
CGC   0.87 (-6.20%)
GE   111.15 (+1.11%)
DIS   79.38 (-0.84%)
AMC   7.79 (-1.52%)
PFE   32.00 (-1.23%)
PYPL   57.09 (-3.12%)
NFLX   378.79 (-0.12%)
LON:SUMM

Summit Therapeutics (SUMM) Share Forecast, Price & News

GBX 20.50
0.00 (0.00%)
(As of 02/21/2020)
Compare
Today's Range
18
20.50
50-Day Range
20.50
20.50
52-Week Range
18
32.50
Volume
280,318 shs
Average Volume
382,504 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

SUMM stock logo

About Summit Therapeutics (LON:SUMM) Stock

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.

SUMM Price History

SUMM Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Summit Therapeutics GAAP EPS of -$0.02
See More Headlines
Receive SUMM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SUMM Company Calendar

Last Earnings
6/12/2019
Today
9/27/2023

Industry, Sector and Symbol

Industry
Drugs - Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Glyn O. Edwards (Age 63)
    CEO & Exec. Director
  • Mr. Erik Ostrowski (Age 46)
    Chief Financial Officer
  • Prof. David Roblin (Age 53)
    COO, Chief Medical Officer and Pres of R&D
  • Prof. Kay Davies (Age 69)
    Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
  • Ms. Michelle Avery
    Director of Investor Relations













SUMM Stock - Frequently Asked Questions

How have SUMM shares performed in 2023?

Summit Therapeutics' stock was trading at GBX 20.50 at the beginning of the year. Since then, SUMM stock has increased by 0.0% and is now trading at GBX 20.50.
View the best growth stocks for 2023 here
.

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics PLC (LON:SUMM) posted its earnings results on Wednesday, June, 12th. The company reported ($3.00) EPS for the quarter, topping analysts' consensus estimates of ($4.00) by $1.00.

What other stocks do shareholders of Summit Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Summit Therapeutics (SMMT), American Airlines Group (AAL), Acadia Healthcare (ACHC), Diana Shipping (DSX), 2570 (JLF.L) (JLF), National Fuel Gas (NFG), Tailored Brands (TLRD), The Weir Group (WEIR) and Acacia Mining (ABGLF).

What is Summit Therapeutics' stock symbol?

Summit Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SUMM."

How do I buy shares of Summit Therapeutics?

Shares of SUMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Summit Therapeutics' stock price today?

One share of SUMM stock can currently be purchased for approximately GBX 20.50.

How can I contact Summit Therapeutics?

Summit Therapeutics' mailing address is 136A Eastern Avenue, ABINGDON, OX14 4SB, United Kingdom. The official website for the company is www.summitplc.com. The company can be reached via phone at +44-1235-443939.

This page (LON:SUMM) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -